Hyderabad, India–based Zenara Pharma has launched a generic version of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir).
Zenara Pharma is naming the generic version of the pill “Paxzen.”
The antiviral is indicated for mild to moderate symptoms of COVID-19.
India’s Central Drugs Standard Control Organisation (CDSCO) cleared the way for authorization of the drug in the country by approving the generic antiviral last month.
FDA authorized Paxlovid in December 2021. Pfizer signaled its intent to seek full approval of the drug in late June.
Zenara Pharma will manufacture its version of the drug at an FDA- and EU-approved facility in Hyderabad.
The company plans to sell the drug at a maximum retail price of 5,200 rupees per box. One box contains 20 tablets (150 ml) of nirmatrelvir and 10 tablets of ritonavir (100 mg).
“We have launched this product in India with an aim to bri…